Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T cells in humanized mice via PD-1 and TIGIT co-targeting
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.09.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Wai Nam Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A∗STAR), 61 Biopolis Drive, Proteos, Singapore 138673, R…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Programmed Cell Death 1 Receptor, Receptors, Immunologic, CD56 Antigen. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Medical Research Council, Biomedical Research Council, Social Justice Fund Northwest.
Abstract (Originalsprache)
In solid tumors, the exhaustion of natural killer (NK) cells and cytotoxic T cells in the immunosuppressive tumor microenvironment poses challenges for effective tumor control. Conventional humanized mouse models of hepatocellular carcinoma patient-derived xenografts (HCC-PDX) encounter limitations in NK cell infiltration, hindering studies on NK cell immunobiology. Here, we introduce an improved humanized mouse model with restored NK cell reconstitution and infiltration in HCC-PDX, coupled with single-cell RNA sequencing (scRNA-seq) to identify potential anti-HCC treatments. A single administration of adeno-associated virus carrying human interleukin-15 reinstated persistent NK cell reconstitution and infiltration in HCC-PDX in humanized mice. scRNA-seq revealed NK cell and T cell subpopulations with heightened PDCD1 and TIGIT levels. Notably, combination therapy with anti-PD-1 and anti-TIGIT antibodies alleviated HCC burden in humanized mice, demonstrating NK cell-dependent efficacy. Bulk-RNA sequencing analysis also revealed significant alterations in the tumor transcriptome that may contribute to further resistance after combination therapy, warranting further investigations. As an emerging strategy, ongoing clinical trials with anti-PD-1 and anti-TIGIT antibodies provide limited data. The improved humanized mouse HCC-PDX model not only sheds light on the pivotal role of NK cells but also serves as a robust platform for evaluating safety and anti-tumor efficacy of combination therapies and other potential regimens, complementing clinical insights.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A∗STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore.
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore 168583, Republic of Singapore.
- Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Division of Gastroenterology and Hepatology, National University Hospital, Singapore 119228, Republic of Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 11…
- Department of Reproductive Medicine, KK Women's and Children's Hospital, Singapore 229899, Republic of Singapore; Experimental Fetal Medicine Group, Yong Loo Lin School of Medicine, National University of Singapore, Sin…
- Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A∗STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore; Department of Microbiology and Immunology, Yong…
Förderung
- National Medical Research Council
- Biomedical Research Council
- Social Justice Fund Northwest
- Ministry of Health -Singapore
- A*STAR Research Entities
Zitieren
APA
Liu, W. N., Harden, S. L., Tan, S. L. W., Tan, R. J. R., Fong, S. Y., Tan, S. Y., Liu, M., Karnik, I., Shuen, T. W. H., Toh, H. C., Fan, Y., Lim, S. G., Chan, J. K. Y., & Chen, Q. (2024). Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T cells in humanized mice via PD-1 and TIGIT co-targeting. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.09.025
Vancouver
Liu WN, Harden SL, Tan SLW, Tan RJR, Fong SY, Tan SY, et al. Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T cells in humanized mice via PD-1 and TIGIT co-targeting. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.09.025
BibTeX
@article{Liu2024,
author = {Liu, Wai Nam and Harden, Sarah L and Tan, Shawn Lu Wen and Tan, Rachel Jun Rou and Fong, Shin Yie and Tan, Sue Yee and Liu, Min and Karnik, Isha and Shuen, Timothy Wai Ho and Toh, Han Chong and Fan, Yong and Lim, Seng Gee and Chan, Jerry Kok Yen and Chen, Qingfeng},
title = {Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T cells in humanized mice via PD-1 and TIGIT co-targeting},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.09.025}
}
EUVIMED